Athenex Regains Rights to KX2-391 in China
March 07, 2019 04:05 ET
|
Athenex, Inc.
BUFFALO, N.Y., March 07, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies...
Athenex於美國皮膚病學會2019年年會上，宣佈最新研發的KX2-391藥膏1%在兩項3期硏究中取得良好療效
March 05, 2019 05:56 ET
|
Athenex, Inc.
研究結果顯示，於KX01-AK-003與KX01-AK-004的硏究中，分別有44%及54%的患者在第57日完全消除AK病灶 KX2-391藥膏的安全性或可成為一項重要的競爭優勢；堅持治療率提高至超過99% 公司將於今日美國東部時間上午8時30分與關鍵意見領袖舉行電話會議 紐約州水牛城, March 05, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc....
Athenex Announces Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting
March 04, 2019 07:00 ET
|
Athenex, Inc.
Results show that 44% and 54% of patients in studies KX01-AK-003 and KX01-AK-004, respectively, achieved 100% AK lesion clearance at Day 57 Safety profile of KX2-391 ointment may be an important...
在美國皮膚病學會年會上以口述方式介紹KX2-391軟膏治療光化性角化病的III期結果後，Athenex將與關鍵意見領袖召開電話會議
February 26, 2019 08:27 ET
|
Athenex, Inc.
紐約州水牛城, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Athenex,...
Athenex to Host Conference Call with Key Opinion Leader Following Oral Presentation of Phase III Results of KX2-391 Ointment in the Treatment of Actinic Keratosis at the American Academy of Dermatology Annual Meeting
February 25, 2019 07:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex, Inc. 將於 2019 年 3 月 11 日公布第四季度和 2018 財年業績
February 14, 2019 19:35 ET
|
Athenex, Inc.
紐約州水牛城, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc.（納斯達克股票代碼：ATNX）是一家專注於發現、研發以及將治療癌症及相關疾病的新型療法商業化的全球生物製藥公司。今日該公司宣布將於 2019 年 3 月 11 日在開市之前發布第四季度及截至 2018 年 12 月 31 日的財政年度的業績。公司將於 2019 年 3 月 11...
Athenex, Inc. to Report Fourth Quarter and Fiscal Year 2018 Earnings Results on March 11, 2019
February 14, 2019 07:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex宣佈將在美國皮膚病學會年會上報告KX2-391軟膏III期研究的兩項最新成果
February 04, 2019 14:25 ET
|
Athenex, Inc.
紐約州布法羅, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX)是一家致力於發現、開發和把治療癌症和相關疾病的新療法商業化的全球生物製藥公司，該公司今天宣布，兩項關於KX2-391軟膏治療光化性角化病的III期研究結果的報告摘要已獲接納在2019年美國皮膚病學會年會的「最新研究成果」（Late-Breaking...
Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
February 04, 2019 07:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex宣佈完成Oraxol第三期研究受試者入選目標
January 09, 2019 11:41 ET
|
Athenex, Inc.
紐約州布法羅, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc.（納斯達克股票代碼：ATNX）（一家全球性生物製藥公司，致力於癌症及相關疾病新療法的研究、開發及商業化），今日宣佈針對轉移性乳腺癌的Oraxol第三期臨床試驗360名受試患者入選目標已按期達成。Athenex亦再次確認該研究的主要試驗數據預期將於2019年中期發佈。 ...